Therapeutic advances in alcohol-associated hepatitis

J Hepatol. 2022 Jun;76(6):1279-1290. doi: 10.1016/j.jhep.2022.03.025.

Abstract

In recent years, there have been important advances in our understanding of alcohol-associated hepatitis (AH), which have occurred in parallel with a surge in clinical trial activity. Meanwhile, the broader medical field has seen a transformation in care paradigms based on emerging digital technologies. This review focuses on breakthroughs in our understanding of AH and how these breakthroughs are leading to new paradigms for biomarker discovery, clinical trial activity, and care models for patients. It portends a future in which multimodal data from genetic, radiomic, histologic, and environmental sources can be integrated and synthesised to generate personalised biomarkers and therapies for patients with AH.

Keywords: Microbiome; Systemic inflammatory response syndrome; Trial design.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Forecasting
  • Hepatitis, Alcoholic* / drug therapy
  • Hepatitis, Alcoholic* / therapy
  • Humans

Substances

  • Biomarkers